← ANALYST RATINGS · TIPRANKS
Lineage Therap (LCTX): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $6.25, the highest $9.00, the lowest $3.00. The average is +539.1% from the last price of $0.98.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.00 → $0.89−10.6% | Hold | −8.6% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.00 → $0.89−11.0% | Hold | −9.1% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.00 → $0.90−9.7% | Hold | −7.7% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.98 → $0.88−11.0% | Hold | −10.4% | Upgrade | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.00 → $0.89−11.0% | Hold | −9.1% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.99 → $0.88−11.0% | Hold | −9.6% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $4.00 | Buy | +309.0% | Reiterated | 24.09.26on TipRanks Sep 25 04:07 | −0.9%next day +8.2% · 5 days −4.1% | ↗ |
| Michael Okunewitch★★★★★★★★★★#11525 · hits 36% · avg −3.3% | Maxim Group | $3.00 | Buy | +206.7% | Reiterated | 11.08.26on TipRanks Aug 12 15:05 | −0.6%next day −2.0% · 5 days −5.0% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $7.00 → $9.00+28.6% | Buy | +820.2% | Reiterated | 07.08.26on TipRanks 10:09 | −3.3%next day +2.8% · 5 days −3.1% | ↗ |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $9.00 | Buy | +820.2% | Reiterated | 06.08.26on TipRanks Aug 7 16:16 | −0.7%next day −3.3% · 5 days −7.4% | ↗ |
| Albert Lowe★★★★★★★★★★#3118 · hits 41% · avg +8.2% | Craig-Hallum | — | Buy | — | Reiterated | 14.07.26on TipRanks Jul 15 16:35 | +0.5%next day −0.4% · 5 days −6.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Lineage Therap
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $6.25 at a price of $0.95 (+554.5%); now: $6.25 at $0.98 (+539.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 5 | 6 | 4 | 5 | 4 |
| Buy | 0 | 0 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.03 (from $-0.04 to $0.00). Last quarter: $-0.03.
Sales
Next quarter’s sales estimate — $2M (from $1M to $8M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Lineage Therap
- CEO: Brian Culley
- Employees: 75
- 2173 Salk Avenue, Carlsbad, CA, 92008, US
- www.lineagecell.com
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Data from the stock’s TipRanks forecast page, read 73 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗